Skip to main content

Advertisement

SpringerLink
Log in

Stereotactic Body Radiation Therapy Salvage for Lymph Node Recurrent Prostate Cancer in the Era of PSMA PET Imaging

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Our understanding of patterns of prostate cancer recurrence after primary treatment of localized disease has significantly evolved since the development of positron emission tomography (PET) agents targeting prostate cancer. Previously, most biochemical recurrences were not associated with imaging correlates when restaging with computed tomography (CT), magnetic resonance imaging (MRI), or bone scintigraphy and, hence, were typically assumed to represent occult metastases. A rising prostate specific antigen (PSA) after previous local therapy prompting a PET scan showing uptake limited to regional lymph nodes is an increasingly common clinical scenario as advanced prostate cancer imaging becomes more widely utilized. The optimal management strategy for patients who have lymph node recurrent prostate cancer is both unclear and evolving, particularly in terms of local and regionally directed therapies. Stereotactic body radiation therapy (SBRT) utilizes ablative radiation doses with steep gradients to achieve local tumor control while sparing nearby normal tissues. SBRT is an attractive therapeutic modality due to its efficacy, favorable toxicity profile, and flexibility to administer elective doses to areas of potential occult involvement. The purpose of this review is to briefly describe how SBRT is being implemented in the era of PSMA PET for the management of solely lymph node recurrent prostate cancer.

Recent Findings

SBRT has been shown to effectively control individual lymph node tumor deposits within the pelvis and retroperitoneum for prostate cancer and is well-tolerated with a favorable toxicity profile. However, a major limitation thus far has been the lack of prospective trials supporting the use of SBRT for oligometastatic nodal recurrent prostate cancer. As further trials are conducted, its exact role in the treatment paradigm of recurrent prostate cancer will be better established. Although PET-guided SBRT appears feasible and potentially beneficial, there is still considerable uncertainty about the use of elective nodal radiotherapy (ENRT) in patients with nodal recurrent oligometastatic prostate cancer.

Summary

PSMA PET has undoubtedly advanced imaging of recurrent prostate cancer, revealing anatomic correlates for disease recurrence that previously went undetected. At the same time, SBRT continues to be explored in prostate cancer with feasibility, a favorable risk profile, and satisfactory oncologic outcomes. However, much of the existing literature comes from the pre-PSMA PET era and integration of this novel imaging approach has led to greater focus on new and ongoing clinical trials to rigorously evaluate this approach and compare to other established treatment modalities utilized for oligometastatic, nodal recurrence of prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Spratt DE, et al. Patterns of lymph node failure after dose-escalated radiotherapy: implications for extended pelvic lymph node coverage. Eur Urol. 2017;71(1):37–43.

    Article  PubMed  Google Scholar 

  2. Jackson WC, et al. Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study. BJU Int. 2017;120(3):351–7.

    Article  PubMed  Google Scholar 

  3. Parker WP, et al. Identification of site-specific recurrence following primary radiation therapy for prostate cancer using C-11 choline positron emission tomography/computed tomography: a nomogram for predicting extrapelvic disease. Eur Urol. 2017;71(3):340–8.

    Article  PubMed  Google Scholar 

  4. Imber BS, et al. Failure patterns by PSMA PET for recurrent prostate cancer after prostatectomy and salvage radiation. Urology. 2022.

  5. Raveenthiran S, et al. The use of (68)Ga-PET/CT PSMA to determine patterns of disease for biochemically recurrent prostate cancer following primary radiotherapy. Prostate Cancer Prostatic Dis. 2019;22(3):385–90.

    Article  CAS  PubMed  Google Scholar 

  6. Raman S, et al. Patterns of prostate cancer recurrence after brachytherapy determined by prostate-specific membrane antigen-positron emission tomography and computed tomography imaging. Int J Radiat Oncol Biol Phys. 2022;112(5):1126–34.

    Article  PubMed  Google Scholar 

  7. Mena E, et al. Novel PET imaging methods for prostate cancer. World J Urol. 2021;39(3):687–99.

    Article  PubMed  Google Scholar 

  8. Galgano, SJ, et al. Defining oligometastatic disease in the new era of PSMA-PET imaging for primary staging of prostate cancer. Cancers (Basel). 2022;14(14).

  9. Schwartz LH, et al. Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer. 2009;45(2):261–7.

  10. Zarzour JG, et al. Lymph node imaging in initial staging of prostate cancer: an overview and update. World J Radiol. 2017;9(10):389–99.

    Article  PubMed  PubMed Central  Google Scholar 

  11. National Comprehensive Cancer Network. Prostate Cancer (Version 3.2022). April 22, 2022]; Available from: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.

  12. Shipley WU, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med. 2017;376(5):417–28.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Carrie C, et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 2019;20(12):1740–9.

    Article  CAS  PubMed  Google Scholar 

  14. Onal C, et al. Oligometastatic bone disease in castration-sensitive prostate cancer patients treated with stereotactic body radiotherapy using 68Ga-PSMA PET/CT: TROD 09–004 study. Clin Nucl Med. 2021;46(6):465–70.

    Article  PubMed  Google Scholar 

  15. Siva S, et al. Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial. Eur Urol. 2018;74(4):455–62.

    Article  PubMed  Google Scholar 

  16. Créhange G, et al. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how? Cancer Radiother. 2014;18(5–6):524–34.

    Article  PubMed  Google Scholar 

  17. Ponti E, et al. Salvage stereotactic body radiotherapy for patients with prostate cancer with isolated lymph node metastasis: a single-center experience. Clin Genitourin Cancer. 2015;13(4):e279–84.

    Article  PubMed  Google Scholar 

  18. Leroy T, et al. Salvage robotic SBRT for local prostate cancer recurrence after radiotherapy: preliminary results of the Oscar Lambret Center. Radiat Oncol. 2017;12(1):95.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Lieng H, et al. Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. Radiother Oncol. 2018;129(2):377–86.

    Article  PubMed  Google Scholar 

  20. Panje C, et al. Radiotherapy for pelvic nodal recurrences after radical prostatectomy: patient selection in clinical practice. Radiat Oncol. 2019;14(1):177.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Cozzi S, et al. Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer: an investigation of 117 pelvic lymph nodes. Strahlenther Onkol. 2022;198(8):700–9.

    Article  PubMed  Google Scholar 

  22. Oehler C, et al. Predictive factors for response to salvage stereotactic body radiotherapy in oligorecurrent prostate cancer limited to lymph nodes: a single institution experience. BMC Urol. 2019;19(1):84.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Burkon P, et al. Stereotactic body radiotherapy for lymph node oligometastases: real-world evidence from 90 consecutive patients. Front Oncol. 2020;10: 616494.

    Article  PubMed  Google Scholar 

  24. Burkoň P, et al. Stereotactic body radiotherapy of lymph node oligometastases. Klin Onkol. 2020;33(2):114–22.

    Article  PubMed  Google Scholar 

  25. Franzese C, et al. Stereotactic/hypofractionated body radiation therapy as an effective treatment for lymph node metastases from colorectal cancer: an institutional retrospective analysis. Br J Radiol. 2017;90(1079):20170422.

    Article  PubMed  PubMed Central  Google Scholar 

  26. • Ost P, et al. Pattern of progression after stereotactic body radiotherapy for oligometastatic prostate cancer nodal recurrences. Clin Oncol (R Coll Radiol). 2016;28(9):e115–20. Most comprehensive report of pattern of recurrence following SBRT for oligorecurrent nodal prostate cancer.

    Article  CAS  PubMed  Google Scholar 

  27. Pinkawa M, et al. Radiotherapy in nodal oligorecurrent prostate cancer. Strahlenther Onkol. 2021;197(7):575–80.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Afshar-Oromieh A, et al. Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017;44(8):1258–68.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Hope TA, et al. Metaanalysis of (68)Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology. J Nucl Med. 2019;60(6):786–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Tran S, et al. Oligorecurrent nodal prostate cancer: long-term results of an elective nodal irradiation approach. Am J Clin Oncol. 2018;41(10):960–2.

    Article  PubMed  Google Scholar 

  31. Zilli T, et al. Recommendations for radiation therapy in oligometastatic prostate cancer: an ESTRO-ACROP Delphi consensus. Radiother Oncol. 2022;176:199–207.

    Article  PubMed  Google Scholar 

  32. • De Bruycker A, et al. PEACE V - Salvage treatment of oligorecurrent nodal prostate cancer metastases (STORM): a study protocol for a randomized controlled phase II trial. BMC Cancer. 2020;20(1):406. First prospective evaluation evaluating metastasis-directed therapy (MDT) versus MDT in conjunction with whole pelvic radiotherapy in patients with oligometastatic recurrent prostate cancer detected on PSMA or choline PET.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Verma J, et al. Dosimetric predictors of duodenal toxicity after intensity modulated radiation therapy for treatment of the para-aortic nodes in gynecologic cancer. Int J Radiat Oncol Biol Phys. 2014;88(2):357–62.

    Article  PubMed  Google Scholar 

  34. • Phillips R, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6(5):650–9. Treatment with SABR for oligometastatic prostate cancer improved outcomes and was enhanced by total consolidation of disease identified by PSMA-targeted positron emission tomography.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Galgano SJ, et al. [(18)F]Fluciclovine-PET guided salvage lymph node dissection following radical prostatectomy. Urology. 2019;132:28–32.

    Article  PubMed  Google Scholar 

  36. McCloskey H, et al. Salvage pelvic lymph node dissection and current state of imaging for recurrent prostate cancer: does a standard exist? Curr Urol Rep. 2020;21(12):62.

    Article  PubMed  Google Scholar 

  37. Rogowski P, et al. Radiotherapy of oligometastatic prostate cancer: a systematic review. Radiat Oncol. 2021;16(1):50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Alabama at Birmingham, Birmingham, AL, USA

    Omar E. Hayek & Soroush Rais-Bahrami

  2. Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, USA

    Soroush Rais-Bahrami & Samuel J. Galgano

  3. O′Neal Comprehensive Cancer Center at UAB, University of Alabama at Birmingham, AL, Birmingham, USA

    Soroush Rais-Bahrami, Andrew McDonald & Samuel J. Galgano

  4. Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, USA

    Andrew McDonald

Authors
  1. Omar E. Hayek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Soroush Rais-Bahrami
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrew McDonald
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Samuel J. Galgano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Samuel J. Galgano.

Ethics declarations

Competing Interests

None relevant to the manuscript content.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hayek, O.E., Rais-Bahrami, S., McDonald, A. et al. Stereotactic Body Radiation Therapy Salvage for Lymph Node Recurrent Prostate Cancer in the Era of PSMA PET Imaging. Curr Urol Rep 24, 471–476 (2023). https://doi.org/10.1007/s11934-023-01174-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-023-01174-5

Keywords

Search

Navigation